Business Wire

UMA Unveils Its Vision for the Next Generation of Humanoid Robots

7.7.2026 15:00:00 EEST | Business Wire | Press release

Share

At Machina Summit, UMA, a Physical AI company, unveiled the design of its first humanoid robot and introduced Real-Time Learning, a learning architecture that enables robots to acquire new skills through demonstration instead of manual programming.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707215927/en/

The announcement comes as aging populations, industrial reshoring, and the energy transition place increasing pressure on labor markets across advanced economies. According to Korn Ferry, the global economy could face a shortage of 85 million workers by 2030, representing as much as $8.5 trillion in unrealized economic output. Against this backdrop, UMA is developing a new generation of intelligent robots built to assist people by taking on physically demanding, repetitive, or hazardous work.

"Demographic, industrial, and environmental challenges all point to the same reality: societies need greater productive capacity," said Rémi Cadène, CEO and co-founder of UMA. "We believe intelligent robots will become part of the solution, not as a substitute for people, but as a new class of tools that enables them to devote more time to what machines will never replace: creativity, judgment, innovation, and caring for others."

Robotics Designed for the Real World

For UMA, humanoid robotics is not about building technology demonstrations. It is about developing robots capable of creating immediate value in environments already built for people, including factories, warehouses, logistics centers, and industrial facilities. Their humanoid architecture enables them to use existing tools, integrate seamlessly into current infrastructure, and collaborate naturally alongside existing teams.

This engineering approach extends beyond hardware. By interacting with the physical world in ways that mirror human behavior, UMA's robots can learn more efficiently from demonstrations, receive guidance when necessary, and continuously improve their performance in operational environments.

While much of today's humanoid robotics industry oscillates between highly mechanical machines that showcase engineering complexity and consumer-inspired products designed to appear friendly, UMA has deliberately chosen a different direction.

UMA has chosen a different direction. This is what UMA calls the dressed machine: its robot combines human-scale proportions with a neutral visor instead of facial features, eliminating ambiguity between person and machine. A soft technical outer shell is paired with intentionally visible mechanical joints, embracing the robot's identity rather than concealing it.

Rather than optimizing for short-lived demonstrations, UMA has engineered its robot to earn trust through everyday use. The objective is not to build a machine that impresses on stage, but one that integrates naturally into industrial operations and becomes a reliable partner over time.

Real-Time Learning: Teaching Robots the Way People Learn

At the heart of UMA's platform is a simple conviction: future robots should learn the way people do.

When people encounter a new task, they observe, experiment, practice, and progressively improve until they master it. Real-Time Learning applies the same principle to robotics by allowing robots to acquire new capabilities from demonstrations, adapt to unfamiliar situations, and continuously refine their execution through experience.

Instead of requiring engineers to manually reprogram robots for every new application, the platform enables robots to continuously learn from their environment, making them significantly more flexible and easier to deploy across a broad range of industrial settings.

As Cadène explains, the industry's challenge is no longer building robots capable of executing individual tasks. The next breakthrough lies in building robots capable of learning new ones.

Building Physical AI in Europe

While today's humanoid robotics race is largely driven by the United States and China, UMA believes Europe offers a unique opportunity to lead the next chapter of Physical AI.

The region combines world-class scientific research, a strong industrial base, and growing demand for automation driven by structural labor shortages. For UMA, Europe is not simply where the company was founded, it is where intelligent robots can create value the fastest.

Technology That Expands Human Potential

Today's unveiling represents more than the introduction of a humanoid robot. It reflects UMA's broader vision for Physical AI: intelligent machines capable of continuously learning, adapting, and working alongside people to address some of society's most pressing demographic, industrial, and environmental challenges.

"We're still at the beginning of this journey," said Cadène. "Humanoid robots will take years to reach large-scale deployment, just as the internet and smartphones required time before transforming entire industries. We believe intelligent robots will reshape the physical economy in much the same way."

"One day, robots will contribute to manufacturing future generations of robots, accelerating their own deployment. But our ambition has never been to replace people. It is to expand what people are capable of, to give everyone more time to create, solve problems, and focus on what makes us uniquely human. That vision guides every scientific, technological, and industrial decision we make at UMA."

About UMA

UMA is a European Physical AI company developing the next generation of intelligent humanoid robots.

Founded in 2025 by Rémi Cadène, Pierre Sermanet, Robert Knight, and Simon Alibert, the company combines expertise in frontier AI, robotics, embodied intelligence, embedded systems, and industrial engineering to build robots capable of learning through demonstration and operating safely in real-world environments.

Headquartered in Paris, with teams across London and Geneva, UMA is building a Physical AI platform designed to help industries address labor shortages while enabling people to focus on higher-value work.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260707215927/en/

Contacts

Press contacts Outcast France
Yana Rogers, yrogers@thisisoutcast.fr, +33 698335048
Nalia Kailali, nkailali@thisisoutcast.fr, +33 652755653

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quaise Energy Raises $134 Million in Initial Close of Series B to Build World’s First Superhot Geothermal Power Plant7.7.2026 15:01:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced the first close of its Series B financing, raising $134 million with additional equity and debt capital expected to close imminently. The round was led by Prelude Ventures, with strategic investments from JERA and Idemitsu, two of Japan's largest energy companies. Nearly all existing investors, including Safar Partners, participated in the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707844187/en/ The proceeds from Series B will fund Project Obsidian, the world’s first commercial superhot geothermal power plant, and the continued development and commercialization of Quaise's millimeter wave drilling system towards depths in excess of 5 km. Project-level equity and debt financing is concurrently being raised as the company advances toward first revenues secured by yet-undisclosed commercial off-take partners. The Series

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development7.7.2026 15:00:00 EEST | Press release

Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. (“Whitehawk,” Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen will provide access to up to five bispecific antibodies using its proprietary RenLite® platform, and Whitehawk will evaluate these in combination with its ADC linker-payload platform technologies. Whitehawk then has the option to advance any resulting BsADC candidates as part of its pipeline. Based on a common light-chain design, RenLite® supports the discovery, screening, and optimization of fully human bispecific antibodies across diverse target combinations, while reducing the risk of light-chain mispairing and providing a robust molecular foundation for subsequent BsADC development. By bringing together the complementary capabilities of Biocytogen and Whitehawk, the collaboration aims to identify BsADC candidates with differentiated targeting profiles and therapeutic potential. “W

Bregal Milestone III Closes at its Increased Hard Cap of €915 Million7.7.2026 14:00:00 EEST | Press release

Bregal Milestone (“Milestone” or the “Firm”), a leading European software private equity firm, today announced the final close of its third fund, Bregal Milestone III (“Fund III” or the “Fund”), at its increased hard cap of €915 million. The Fund was oversubscribed and marks a significant broadening of the Firm’s global investor base. Completed in eight months from first close and achieved against a challenging fundraising environment, the result reflects the strength of Milestone’s AI-centric approach and demonstrable track record. Jan Bruennler, Philippe Lautenberg and Cyrus Shey, Co-Founders and Managing Partners at Bregal Milestone, commented: “Bregal Milestone III reflects strong conviction in our approach to investing in mission-critical European software, AI and cybersecurity businesses and helping them scale. We are thankful for the support and confidence shown by our limited partners, both longstanding and new, and remain focused on executing the strategy that has defined Mile

HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics7.7.2026 13:39:00 EEST | Press release

HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707870943/en/ HTEC, a global technology and AI engineering company headquartered in Silicon Valley, and Embotech, a global leader in safety-certified Level 4 autonomous driving solutions for industrial logistics, today announced a strategic partnership to scale deployment of Embotech's autonomous driving solutions across vehicle platforms, customer programmes and industrial sites. The partnership comes as Embotech’s proven autonomous driving solutions are being adopted across a growing number of vehicle platforms

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile7.7.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first Phase 3 trial, COMP005, which demonstrated rapid onset and durable response to at least 6 months, with a generally well-tolerated and safe profile in people living with TRD. The COMP360 Phase 3 program participants represent a highly chronic TRD population. In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. Within the context of this severe population, 39% of participants in the 25 mg arm achieved a clinically m

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye